June 2nd 2023
Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.
August 23rd 2022
Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical CancerJune 6th 2022
Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.